• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PSMA radioligand therapy rechallenging: expanding the therapeutic possibilities in metastatic castration resistant prostate cancer.

作者信息

Volpe Fabio, Piscopo Leandra, Klain Michele

机构信息

Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

Radiology Department of Surgery, Medicine and Pharmacy, University of Sassari, Sassari, Italy.

出版信息

Eur J Nucl Med Mol Imaging. 2024 Nov;51(13):4163-4164. doi: 10.1007/s00259-024-06870-z.

DOI:10.1007/s00259-024-06870-z
PMID:39096364
Abstract
摘要

相似文献

1
PSMA radioligand therapy rechallenging: expanding the therapeutic possibilities in metastatic castration resistant prostate cancer.前列腺特异性膜抗原放射性配体疗法再挑战：拓展转移性去势抵抗性前列腺癌的治疗可能性
Eur J Nucl Med Mol Imaging. 2024 Nov;51(13):4163-4164. doi: 10.1007/s00259-024-06870-z.
2
Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.镥-177 标记 PSMA 配体治疗转移性去势抵抗性前列腺癌的疗效和生存的真实世界数据分析。
Target Oncol. 2021 May;16(3):369-380. doi: 10.1007/s11523-021-00801-w. Epub 2021 Mar 9.
3
A Single-Arm, Low-Dose, Prospective Study of Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.一项关于Lu-EB-PSMA放射性配体疗法治疗转移性去势抵抗性前列腺癌患者的单臂、低剂量前瞻性研究。
J Nucl Med. 2023 Apr;64(4):611-617. doi: 10.2967/jnumed.122.264857. Epub 2022 Nov 3.
4
Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Ac-PSMA-617 Radioligand Therapy.转移性去势抵抗性前列腺癌患者接受 Ac-PSMA-617 放射性配体治疗的总生存和无病生存的预测因素。
J Nucl Med. 2020 Jan;61(1):62-69. doi: 10.2967/jnumed.119.229229. Epub 2019 May 17.
5
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.镥-PSMA-I&T 放射性配体治疗转移性去势抵抗性前列腺癌的治疗结果、毒性和预测因素。
Eur Urol. 2019 Jun;75(6):920-926. doi: 10.1016/j.eururo.2018.11.016. Epub 2018 Nov 22.
6
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.镥 177-PSMA-617 治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
7
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.177Lu-PSMA-617 放射性配体治疗转移性去势抵抗性前列腺癌的成本效益分析。
J Natl Compr Canc Netw. 2023 Jan;21(1):43-50.e2. doi: 10.6004/jnccn.2022.7070.
8
Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing Lu-PSMA-617 radioligand therapy.接受镥-PSMA-617放射性配体治疗的转移性去势抵抗性前列腺癌（mCRPC）患者肝转移灶的反应和结局
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):103-112. doi: 10.1007/s00259-020-04828-5. Epub 2020 May 6.
9
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for Lu-labelled PSMA Radioligand Therapy.低前列腺特异性膜抗原 (PSMA) 表达的转移性去势抵抗性前列腺癌患者预后不良，被认为不符合 Lu-标记 PSMA 放射性配体治疗标准。
Eur Urol Oncol. 2019 Nov;2(6):670-676. doi: 10.1016/j.euo.2018.11.007. Epub 2018 Dec 13.
10
Therapeutic response and safety of radioligand therapy with Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients.镥 PSMA-617 放射性配体治疗转移性去势抵抗性前列腺癌患者的疗效和安全性。
Med Oncol. 2024 Aug 13;41(9):226. doi: 10.1007/s12032-024-02466-7.

本文引用的文献

1
Efficacy and safety of rechallenge [Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study).在 mCRPC 患者初始部分缓解后重新使用 [Lu]Lu-PSMA-617 RLT 的疗效和安全性：前瞻性登记研究（REALITY 研究）的评估。
Eur J Nucl Med Mol Imaging. 2024 Nov;51(13):4151-4162. doi: 10.1007/s00259-024-06825-4. Epub 2024 Jul 15.
2
Safety and Efficacy of Extended Therapy with [Lu]Lu-PSMA: A German Multicenter Study.LuLu-PSMA 延长治疗的安全性和疗效：一项德国多中心研究。
J Nucl Med. 2024 Jun 3;65(6):909-916. doi: 10.2967/jnumed.123.267321.
3
The Outcome and Safety of Re-challenge Lutetium-177 PSMA (Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report.
低剂量多西他赛作为放射增敏剂再挑战镥-177 PSMA（Lu-PSMA）治疗的疗效与安全性——转移性去势抵抗性前列腺癌（mCRPC）中一种有前景的联合治疗方案：病例报告
Nucl Med Mol Imaging. 2021 Jun;55(3):136-140. doi: 10.1007/s13139-021-00696-5. Epub 2021 Apr 13.
4
Efficacy and Safety of [Ac]Ac-PSMA-617 Augmented [Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis.[锕]Ac-PSMA-617增强[镥]Lu-PSMA-617放射性配体疗法治疗预后不良的高度进展性mCRPC患者的疗效和安全性
Pharmaceutics. 2021 May 14;13(5):722. doi: 10.3390/pharmaceutics13050722.
5
Ac-PSMA-617 for Therapy of Prostate Cancer.Ac-PSMA-617 用于前列腺癌的治疗。
Semin Nucl Med. 2020 Mar;50(2):133-140. doi: 10.1053/j.semnuclmed.2020.02.004. Epub 2020 Feb 14.
6
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.Lu-PSMA-617 治疗剂在转移性去势抵抗性前列腺癌中的扩大 50 例单中心前瞻性 II 期试验的长期随访和再治疗结果。
J Nucl Med. 2020 Jun;61(6):857-865. doi: 10.2967/jnumed.119.236414. Epub 2019 Nov 15.
7
TheraP: a randomized phase 2 trial of Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).TheraP：一项关于镥-PSMA-617诊疗性治疗与卡巴他赛治疗进展性转移性去势抵抗性前列腺癌的随机2期试验（临床试验方案ANZUP 1603）
BJU Int. 2019 Nov;124 Suppl 1:5-13. doi: 10.1111/bju.14876. Epub 2019 Oct 22.
8
EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT).EANM 程序指南：镥[177Lu]标记的 PSMA 配体（Lu-PSMA-RLT）放射性核素治疗。
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22.
9
Outcome and safety of rechallenge [Lu]Lu-PSMA-617 in patients with metastatic prostate cancer.[镥-177]Lu-PSMA-617 再次治疗转移性前列腺癌患者的疗效和安全性。
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1073-1080. doi: 10.1007/s00259-018-4222-x. Epub 2018 Nov 24.
10
Early Experience of Rechallenge Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer.晚期前列腺癌患者初始 Lu-PSMA 放射性配体治疗后良好应答后的再挑战经验。
J Nucl Med. 2019 May;60(5):644-648. doi: 10.2967/jnumed.118.215715. Epub 2018 Nov 15.